Abstract:Background CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6), a programmed death-ligand 1 (PD-L1) regulator, is widely expressed in various tumors and regulates the immune microenvironment. However, its prognostic value remains controversial, and the roles of CMTM6 in colorectal cancer (CRC) are still unknown. In this study, we aimed to elaborate the expression patterns of CMTM6 and PD-L1 in CRC and investigate their relationship with the infiltration of T cells and the prognosis of patients with CRC. Methods Analysis of CMTM6 mRNA levels, gene ontology enrichment analysis and single-sample gene set enrichment analysis were performed in a The Cancer Genome Atlas colon cancer cohort. The expression of CMTM6 and PD-L1 and the infiltration of T cells in tumor tissues from our cohort containing 156 patients with CRC receiving adjuvant chemotherapy and 77 patients with CRC without chemotherapy were examined by immunohistochemistry assay. Results CMTM6 expression was upregulated in CRC compared with normal colon tissues, and CMTM6 levels were lower in advanced tumors than in early-stage tumors. High expression of CMTM6 correlated with lower pT stage and more CD4 + /CD8 + tumor-infiltrating lymphocytes (TILs) and predicted a favorable prognosis in CRC. PD-L1 was expressed in CRC tissues at a low level, and PD-L1 positivity in tumor stroma (PD-L1(TS)), but not PD-L1 positivity in cancer cells (PD-L1(CC)), was associated with an increased density of CD4 + TILs and a favorable prognosis. The coexpression status of CMTM6 and PD-L1(TS) divided patients with CRC into three groups with low, moderate and high risks of progression and death, and patients with CMTM6 High /PD-L1(TS) + status had the longest survival. Moreover, the prognostic value of CMTM6/PD-L1 expression was more significant in patients with CRC treated with adjuvant chemotherapy than in those not treated with chemotherapy. Conclusion CMTM6 has a critical impact on the immune microenvironment and can be used as an independent prognostic factor for CRC. The coexpression status of CMTM6 and PD-L1 can be used as a new classification to stratify the risk of progression and death for patients with CRC, especially for patients receiving adjuvant chemotherapy. These findings may provide insights into improving responses to immunotherapy-included comprehensive treatment for CRC in the future.

CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer

Prognostic Implications of Pan-cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients

CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer

Change of CMTM7 expression, a potential tumor suppressor, is associated with poor clinical outcome in human non-small cell lung cancer

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer

Coexpression of CMTM6 and PD-L1 As a Predictor of Poor Prognosis in Macrotrabecular-Massive Hepatocellular Carcinoma

14P High CMTM6 and PD-L1 co-expression predict metastasis and poor prognosis in oesophageal squamous cell carcinoma

CMTM6, a potential immunotherapy target

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer

Interstitial Tumor-Associated Macrophages Combined with Tumor-Derived Colony-Stimulating Factor-1 and Interleukin-6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer.

Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Identification of an m6A Regulators-Mediated Prognosis Signature For Survival Prediction and Its Relevance to Immune Infiltration in Melanoma

CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer

Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity

MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer

Comprehensive Analysis of the Prognosis for Chemokine-Like Factor MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma

The Pathological Tissue Expression Pattern and Clinical Significance of M6a‐regulatory Genes in Non‐small Cell Lung Cancer

CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway